COMMUNIQUÉS West-GlobeNewswire

ImageneBio to Participate in Leerink Global Healthcare Conference
26/02/2026
SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA, “Imagene,” or the “Company”), today announced management will participate in a fireside chat and hold one-on-one meetings at the 2026 Leerink [...]
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus
26/02/2026
WARREN, N.J. and ROYAL OAK, Mich., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN ) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent [...]
NETHERTON NOW Recognizes Rare Disease Day and Highlights Growing Global Awareness of Netherton Syndrome
26/02/2026
Videos on the NETHERTON NOW website have been viewed 2 million times with 24 million impressions ASHBURN, Va., Feb. 26, 2026 (GLOBE NEWSWIRE) -- In recognition of Rare Disease Day® 2026, Quoin Pharmaceuticals Ltd. ( [...]
Iovance Biotherapeutics to Present at Upcoming Conferences
26/02/2026
SAN CARLOS, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating [...]
PharmAla Signs Drug Donation Agreement for MDMA-Assisted Therapy Clinical Trial in Fibromyalgia
26/02/2026
TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) , a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives [...]
Vericel Reports Fourth Quarter and Full-Year 2025 Financial Results
26/02/2026
Total Revenue of $276.3 Million, with MACI Revenue Growth of 21% to $239.5 Million Net Income Growth of 59% to $16.5 Million Fourth Quarter Total Revenue and MACI Revenue Growth of 23% Record Fourth Quarter Gross Margin [...]
Highridge Medical Begins a Limited Launch of the activL® Lumbar Disc with Strong Early Surgeon Adoption
26/02/2026
Surgeons complete initial cases at premier disc replacement centers across the United States. WESTMINSTER, Colo., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Highridge Medical, a leading privately held global spine company with a [...]
The International Myeloma Foundation Invites the Myeloma Community to Demonstrate the Spirit of #MoreThanMyeloma for 2026 Myeloma Action Month
26/02/2026
STUDIO CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Every March, the International Myeloma Foundation (IMF) leads Myeloma Action Month — an annual global awareness campaign that raises awareness and inspires action [...]
U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma’s Patent 11,697,028 To Be Unpatentable
26/02/2026
WOBURN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy (“PDT”), today announced that [...]
Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
26/02/2026
Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell therapy as same-day hospital discharge Four systemic sclerosis patients and the first [...]
Mixie Technologies, Inc. (OTC: PHCG) Secures Minority Ownership Stake in Mixie Realty LLC
26/02/2026
Transaction expands Mixie’s platform strategy into immersive real estate visualization and technology-enabled property management DENVER, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Mixie Technologies, Inc. (OTC: PHCG), formerly [...]
OneMedNet Partners with ViuHealth to Enhance Autoimmune Dataset Scale, Accelerating Recurring Revenue from Life Sciences and AI Customers
26/02/2026
MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced a strategic partnership with ViuHealth, a [...]
SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247
26/02/2026
Results from IV Phase 1 SAD/MAD Trial Expected in 2026 JERSEY CITY, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent [...]
Addgene Appoints Greg Crescenzi as Vice President of Global Commercial Strategy and Partnerships
26/02/2026
WATERTOWN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Addgene, an organization committed to accelerating discovery and innovation by providing a vast catalog of expertly curated and quality-controlled research tools [...]
Glow Holdings, Inc. Launches New Corporate Website
26/02/2026
HOUSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Glow Holdings, Inc. (OTC: GLOH), doing business as GlohCo, an emerging healthtech company developing AI-powered software and data-driven tools for mental health, behavioral [...]
Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026
26/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for [...]
Entera Bio to Participate in the Leerink Partners 2026 Global Healthcare Conference
26/02/2026
TEL AVIV, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced that the Company’s [...]
Privia Health Reports Fourth Quarter and Full-Year 2025 Financial Results
26/02/2026
All 2025 Operating and Financial Metrics At or Above High End of Guidance Ranges Full-year 2025 Net Income +59.3% from 2024 Full-year 2025 Adjusted EBITDA of $125.5 Million, +38.8% from 2024 Full-year 2025 Net Cash [...]
Certara Reports Fourth Quarter 2025 Financial Results; Provides Full Year 2026 Guidance
26/02/2026
FY 2025 Revenue of $418.8M (9% growth) and Adj. EBITDA of $134.5M (10% growth) Fourth Quarter Revenue of $103.6M (3% growth) and Adj. EBITDA of $32.5M (-3% decline) FY 2026 Revenue Growth of 0-4% FY 2026 Adjusted EBITDA [...]

Pages